Vertex to Acquire Alpine Immune Sciences for ~$4.9B

Share this


Vertex to Acquire Alpine Immune Sciences for ~$4.9B


  • Vertex has signed a definitive agreement to acquire Alpine Immune Sciences for $65 per unit making it a total of ~$4.9B in cash. The transaction will conclude in the Q2’24
  • The acquisition will add Alpine’s povetacicept (ALPN-303) to the company’s portfolio, which demonstrated effectiveness in the P-II study of IgA nephropathy. The drug’s P-III clinical evaluation in anticipated in H2’24
  • Povetacicept is a dual BAFF (B cell activating factor) & APRIL (a proliferation inducing ligand) cytokines antagonist which are responsible for the pathogenesis of various autoimmune diseases by activating, differentiating & sustaining B cells, T cells & innate immune cells

Ref: Vertex | Image: Vertex

Related News:- Vertex Receives CHMP’s Positive Opinion for Kalydeco as a Treatment of Cystic Fibrosis in Infants

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions